Article | September 21, 2021

Key Considerations: How CDMOs Can Maximize Productivity And Scalability

By Kevin Mullen, Jason Lukasek, and Jonathan Foster, Thermo Fisher Scientific

pharma manufacturing vials fill finish 980809416

Flexibility is key to successful operation in this quickly evolving paradigm, fueling increased industry reliance on contract development and manufacturing organizations (CDMOs).  A recent BioPlan Associates, Inc., survey identified outsourcing growth, the need for bioprocessing production flexibility, supply chain diversification, and increased leverage of single-use systems as trends that will drive biopharmaceutical R&D and manufacturing in 2021 and beyond. To meet industry demand for these capabilities, CDMOs must grow and evolve, scaling up through innovative workflows — without sacrificing product quality or speed to market.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: